Characterization of Receptor Binding Affinity for Vascular Endothelial Growth Factor with Interferometric Imaging...

Area of Science:

• Ophthalmology
• Biotechnology
• Biomedical Engineering

Background:

• Wet age-related macular degeneration (AMD) is a primary cause of vision loss in industrialized nations.
• Biologics are effective treatments for wet AMD but are costly.
• Accurate binding affinity measurements are crucial for ensuring biologic efficacy and comparing drugs.

Purpose of the Study:

• To evaluate and compare the in vitro Vascular Endothelial Growth Factor (VEGF) binding affinity of bevacizumab and aflibercept.
• To assess the utility of the Interferometric Reflectance Imaging Sensor (IRIS) system for quantitative binding measurements of biologics.

Main Methods:

• Quantitative binding measurements of bevacizumab and aflibercept to recombinant human VEGF (rhVEGF) were performed using an IRIS system.
• Therapeutic molecules were immobilized on a microarray support for real-time binding interaction analysis.
• The IRIS system utilizes silicon-based semiconductor chips for enhanced signal detection and multiplexed analysis.

Main Results:

• Aflibercept demonstrated a higher binding affinity to VEGF compared to bevacizumab.
• These results align with previous findings obtained through ELISA and Surface Plasmon Resonance (SPR) methods.
• The IRIS system provided reliable and quantitative binding data.

Conclusions:

• Aflibercept exhibits superior VEGF binding affinity over bevacizumab for wet AMD treatment.
• The IRIS system is a promising, cost-effective sensor technology for evaluating biologic therapeutic agents.
• IRIS technology offers potential for future applications in drug development and comparative efficacy studies.